With simultaneous use with drugs that have a depressing effect on the central nervous system, may significantly increased inhibitory action on the central nervous system, hypotensive effect, respiratory depression.
With simultaneous use with drugs possessing anticholinergic activity may increase anticholinergic effects.
With simultaneous use may increase the action of sympathomimetic funds for the cardiovascular system and increase the risk of cardiac arrhythmias, tachycardia, severe hypertension.
With simultaneous use with antipsychotics (neuroleptics) are relatively suppressed metabolism, with a reduction in the threshold of convulsive readiness.
With simultaneous use with antihypertensive drugs (except clonidine, guanethidine and their derivatives) may increase the antihypertensive action and the risk of orthostatic hypotension.
With simultaneous use with MAO inhibitors may develop a hypertensive crisis; with clonidine, guanethidine – may decrease the hypotensive effect of clonidine or guanethidine; with barbiturates, carbamazepine – may decrease the action of amitriptyline due to increasing its metabolism.
A case of serotonin syndrome while the use of sertraline.
In an application with sucralfate decreases absorption of amitriptyline; with fluvoxamine – increases the concentration of amitriptyline in blood plasma and the risk of toxic action; with fluoxetine – increased concentration of amitriptyline in plasma and develop toxic reactions due to inhibition of isoenzyme CYP2D6 under the influence of fluoxetine; with quinidine – may slow metabolism of amitriptyline; cimetidine – possibly slowing down the metabolism of amitriptyline, increasing its plasma concentration and the development of toxic effects.
With simultaneous application of ethanol increases the effects of ethanol, especially during the first few days of therapy.